Skip to main content

$0.350 0.020 (6.06%)

High

$0.35

Low

$0.32

Trades

32

Turnover

$102,945

Volume

313,271
30 June 2023 at 4:10pm
Register to track OCC and receive email alerts.
Subject
OCC Ann: Ortho-ATI Shoulder Tendon Study Update Revised

OCC Ann: Ortho-ATI Shoulder Tendon Study Update

OCC Ann: Appendix 4E and Annual Report to Shareholders

OCC Ann: Appendix 4G

OCC Ann: Annual General Meeting

OCC Ann: CelGro Nerve Study Results Presented at AOA annual Meeting

OCC Ann: Notice under Section 708(A) of the Corporations Act

OCC Ann: Application for quotation of securities - OCC

OCC Ann: Notice under Section 708(A) of the Corporations Act

OCC Ann: Application for quotation of securities - OCC

OCC Ann: CelGro Facilitates Lymphatic Vessel Regeneration Updated

OCC Ann: CelGro Facilitates Lymphatic Vessel Regeneration

OCC Ann: Appendix 4C - Quarterly

OCC Ann: Orthocell Appoints Exclusive Distributor in Australia

OCC Ann: Notice under Section 708(A) of the Corporations Act

OCC Ann: Application for quotation of securities - OCC

OCC Ann: Application for quotation of securities - OCC

OCC Ann: Application for quotation of securities - OCC

OCC Ann: Positive CelGro Nerve Regeneration Results

OCC Ann: OCC Secures Patents for Sutureless Repair of Soft Tissue

OCC Ann: Proposed issue of Securities - OCC

OCC Ann: New Collagen Rope Patent for CelGro Platform Technology

OCC Ann: Appendix 2A and Notice Under Section 708A

OCC Ann: Appendix 4C - Quarterly

OCC Ann: CelGro Study Results Open Up New US Market Access Strategy

OCC Ann: Change of Director's Interest Notice LL

OCC Ann: Appendix 2A and Notice Under Section 708A

OCC Ann: CelGro gains Australian reimbursement

OCC Ann: Half Yearly Report and Accounts

OCC Ann: Appendix 2A and Notice Under Section 708A

OCC Ann: Orthocell receives new US patent for CelGro

OCC Ann: Proposed issue of Securities - OCC

OCC Ann: Ceasing to be a substantial holder

OCC Ann: CelGro Recommended for Reimbursement

OCC Ann: Appendix 4C - Quarterly

OCC Ann: Change of Director's Interest Notice * 5

OCC Ann: Novel Surgical Treatment for Tendon Repair

OCC Ann: Appendix 2A

OCC Ann: Orthocell Receives A$2.3m R&D Tax Incentive Refund

OCC Ann: Orthocell Receives First US CelGro Product Approval

OCC Ann: Trading Halt

OCC Ann: Pause in Trading

OCC Ann: Appendix 2A and Notice Under Section 708A

OCC Ann: CelGro Receives Australian Market Approval

OCC Ann: CelGro Completes Pivotal Step in TGA Approval Process

OCC Ann: Change of Director's Interest Notice * 4

OCC Ann: Positive Results in CelGro Nerve Repair Study

OCC Ann: Trading Halt

OCC Ann: Appendix 4C - Quarterly

OCC Ann: Appendix 3G

Register to track OCC and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
MSB
OPT
PAR
PYC
RAC
TLX